To ascertain if hydroxychloroquine (HCQ)/chloroquine (CLQ) and other conventional disease-modifying anti-rheumatic drugs (cDMARDs) use, and rheumatic diseases per se, may be associated with COVID-19-related risk of hospitalization and mortality.
Risk of coronavirus disease 2019 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional disease-modifying anti-rheumatic drugs in Italy / Alegiani, Stefania Spila; Crisafulli, Salvatore; Rossi, Paolo Giorgi; Mancuso, Pamela; Salvarani, Carlo; Atzeni, Fabiola; Gini, Rosa; Kirchmayer, Ursula; Belleudi, Valeria; Kurotschka, Peter Konstantin; Leoni, Olivia; Ludergnani, Monica; Ferroni, Eliana; Baracco, Susanna; Massari, Marco; Trifirò, Gianluca. - In: RHEUMATOLOGY. - ISSN 1462-0324. - 60:Spec. Iss.(2021), pp. SI25-SI36. [10.1093/rheumatology/keab348]
Risk of coronavirus disease 2019 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional disease-modifying anti-rheumatic drugs in Italy
Salvarani, Carlo;
2021
Abstract
To ascertain if hydroxychloroquine (HCQ)/chloroquine (CLQ) and other conventional disease-modifying anti-rheumatic drugs (cDMARDs) use, and rheumatic diseases per se, may be associated with COVID-19-related risk of hospitalization and mortality.Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris